Exploring a Multi-Dose Regenerative Approach
Mesenchymal stem cells (MSCs) continue to be studied for their ability to release biological signals that may help support tissue repair, blood vessel health, and a balanced inflammatory response.
While many clinical studies have investigated a single MSC treatment, researchers are also interested in whether multiple doses could provide more sustained support over time.
The 2026 PRIME-HFrEF trial explored this idea using umbilical cord-derived mesenchymal stem cells (UC-MSCs) in people with reduced cardiac function. The study was designed primarily to evaluate the safety of giving several intravenous MSC infusions while also looking for possible changes in heart function.
Inside the PRIME-HFrEF Trial
The randomized, double-blind, placebo-controlled study enrolled 40 patients. Participants continued receiving modern standard cardiac medications throughout the trial.
Those assigned to the UC-MSC group received three intravenous infusions, each spaced six weeks apart. Researchers followed participants for up to 360 days.
The study examined several areas, including:
- Overall safety and serious adverse events
- Left and right ventricular function
- Changes in the size and volume of the heart chambers
- Blood and laboratory measurements
Using repeated intravenous infusions was particularly interesting because this method allows MSCs to be administered without a more invasive procedure.
Encouraging Changes in Right-Heart Function
One of the most notable findings involved the right ventricle, the chamber responsible for pumping blood toward the lungs.
Patients who received UC-MSCs experienced significant improvements in right ventricular measurements compared with the placebo group. In particular, researchers found meaningful reductions in right ventricular end-systolic volume, which reflects the amount of blood remaining in the chamber after it contracts.
This improvement remained evident in the later follow-up period, suggesting that the changes observed were not limited to immediately after treatment.
Researchers also observed improvements in left ventricular ejection fraction in the UC-MSC group over the year. However, the placebo group improved as well, so there was no significant difference between the groups for this measurement.
What the Safety Findings Showed
Safety was the primary focus of the trial, and the researchers found no significant difference in the rate of serious adverse events between the UC-MSC and placebo groups.
Other reassuring findings included:
- Liver and kidney function remained within normal ranges
- Imaging showed no evidence of unwanted tissue growth or tumor formation
- Rates of abnormal heart rhythms were similar between groups
Researchers did observe temporary increases in certain blood-clotting markers following repeated UC-MSC infusions. These levels later returned toward the normal range, providing useful information that may help guide monitoring and treatment strategies in future studies.
Why Repeat MSC Dosing Matters
MSCs are thought to work largely through the signals they release rather than by permanently replacing damaged cells.
These signals may influence processes involved in:
- Supporting blood vessel formation
- Regulating inflammation
- Protecting surrounding cells
- Reducing tissue stress and fibrosis
Because MSCs may remain in the body for a limited period, repeated treatments are being investigated as one possible way to extend their biological effects.
The PRIME-HFrEF trial adds important human clinical data by showing that three intravenous UC-MSC treatments could be administered within a structured clinical setting, while also producing encouraging changes in right ventricular measurements.
Moving Cardiac Regenerative Research Forward
This study represents another meaningful step in understanding how umbilical cord-derived MSCs may be used in regenerative cardiovascular research.
The multi-dose approach was associated with promising improvements in right-heart measurements, while serious adverse event rates remained comparable between the treatment and placebo groups.
Although larger studies will be needed to better understand effectiveness and refine treatment protocols, the PRIME-HFrEF trial provides valuable insight into how repeated UC-MSC infusions may be explored as part of future regenerative strategies for supporting cardiac function.
Source
Han W, Jiao Y, Chen W, et al. PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure. Signal Transduction and Targeted Therapy. 2026;11:112. doi: 10.1038/s41392-026-02678-5. Available from: https://www.nature.com/articles/s41392-026-02678-5
Related Treatment Pages